If you have been reading about alpha-MSH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
For services to Higher Education. Veronica Mary Coxon. For services to WRVS in Sutton Coldfield, West Midlands. Freda Elizabeth Moody Craig. For services to Golf Jacqueline Ainslie Diana Craig. For services to the Gurkha Welfare Trusts. Sheila Elizabeth Craine. For services to the community in Merseyside. Stephen James Croad, lately Head of Record, National Buildings, Royal Commission on the Historical Monuments of England. Eric Kenneth Crompton, Business Development Manager, Matra Marconi Space UK Ltd. For services to the Space Industry. June Pamela Cromwell, Technician, Southern Water. For services to the Water Industry. The Reverend Hugh Geoffrey Cross. For services to Ecumenical Relations in Milton Keynes, Buckinghamshire. Joaquim Jose Cubertino, Head Waiter, Catering Department, St Thomas' Hospital, London. For services to Health Care. Frederick Ernest Cullen, Administrative Assistant, the Benefits Agency, Department of Social Security. The Reverend Richard Cullington, , lately Officiating Chaplain, RAF St Mawgan. For services to the Royal Air Force. Kathleen Curnock. For services to Voluntary Services. Charles Starr Curry, Editor, New Milton Advertiser & Lymington Times. For services to Journalism in Hampshire. Gerald Cutcliffe, Wildlife Ranger, Forestry Commission. Margaret D'Arcy, Actress. For services to Drama. Peter Aubrey Victor D'Costa, Higher Executive Officer, Department of the Environment. Rose D'Costa, Personal Secretary, Department of Transport. John Christopher Dale, Managing Director, John Dale Ltd. For services to Industry in Wales.
A common belief among users is that the smoke of a hookah (waterpipe, narghile) is significantly less dangerous than that from cigarettes. The water moisture induced by the hookah makes the smoke less irritating and may give a false sense of security and reduce concerns about true health effects. Doctors at institutions including the Mayo Clinic have stated that use of hookah can be as detrimental to a person's health as smoking cigarettes, and a study by the World Health Organization also confirmed these findings. Although the smoking effects are similar to a cigarettes, due to the manner in which a hookah is utilized, smoking hookah may potentially absorb a higher amount of toxic substances, compared to cigarette smokers. Each hookah session typically lasts more than 40 minutes, and consists of 50 to 200 inhalations that each range from 0.15 to 0.50 liters of smoke. In an hour-long smoking session of hookah, users consume about 100 to 200 times the smoke of a single cigarette; A study in the Journal of Periodontology found that water pipe smokers were marginally more likely than regular smokers to show signs of gum disease, showing rates 5-fold higher than non-smokers rather than the 3.8-fold risk that regular smokers show. A systematic review on waterpipe smoking and cancer reports that waterpipe smokers had significantly higher, up to six times odds of lung cancer compared to non-smokers. A study on hookah smoking and cancer in Pakistan was published in 2008. Its objective was "to find serum CEA levels in ever/exclusive hookah smokers, i.e.
=== 19 April === South Korean President Yoon Suk-yeol, announced that they would send military aid to Ukraine, if Russia carries out any more large-scale attacks against civilians in Ukraine. Dmitry Medvedev, Deputy Secretary of the Security Council of Russia and former Russian President, responded by saying that if South Korea were to send military aid to Ukraine, Russia would respond by sending military aid to the Democratic People's Republic of Korea on a "...quid pro quo" basis. President Yoon drew comparisons between the war in Ukraine and the Korea War of 1950–53 and how the international community supported South Korea. Several foreign volunteers were killed by Russian forces in Bakhmut, including: Dmitry Petrov from Russia; Finbar Cafferkey from Ireland; and Cooper “Harris” Andrews from the United States. The death of Cafferkey caused a strain in Ireland–Russia relations.
The company was founded in Pittsburgh, Pennsylvania, in 1902 by Chester Garfield Fisher (1881–1965), originally called the "Scientific Materials Co.". After obtaining his degree in engineering at Western University of Pennsylvania (now University of Pittsburgh), C.G. Fisher purchased the stockroom of the Pittsburgh Testing Laboratory. Fisher became a supplier of lab equipment and reagents for the area's industrial research. Early products included microscopes, burets, pipettes, litmus, balances, colorimeters, dissecting kits, and anatomical models. The first catalog, the 400 page Scientific Materials Co. Catalog of Laboratory Apparatus & Supplies, was published in 1904. Fisher established an R&D lab at his company in 1915. Edwin Fisher, Chester's brother, developed the Meker-Fisher burner in 1921, an advancement on the design of the Bunsen burner. The company manufactured an electric-combustion furnace and combustion train for analyzing carbon levels in steel, and an electrically heated and thermostatically controlled bacteriological incubator. In 1925, the company purchased Montreal-based Scientific Supplies, Ltd. The same year, the company was renamed Fisher Scientific. In 1940, Fisher Scientific acquired the New York supply company Eimer & Amend, which was founded in 1851 by Bernard G. Amend. Aiken Fisher, Chester's oldest son, became president of the company in 1949. In 1955, Fisher established a chemical manufacturing facility in Fair Lawn, New Jersey. In 1957, the company purchased the New York–based medical apparatus supply company E. Machlett & Sons.
== Patents == Magnetic method of pipe-line inspection, (1950). Photoelectric colorimeter, (1950). Refractive index measurement of fluids, (1951). Process for the purification of spent sulphuric acid, (1952). Infrared gas analyzer, (1954). Improvements in and relating to the preparation of oil solutions of highly basic polyvalent metal salts of organic acids, (1956). Process for removing coal and carbonaceous material from used sulfuric acid, (1957). Improvements in or relating to apparatus for measuring vapour pressure, (1957). Improvements in and relating to the preparation of basic polyvalent metal salts of organic acids, (1958). Sulphonation of organic liquids, (1960). A method of and apparatus for separating liquid phases, (1965). Rotary separation of viscous pseudo-plastics, (1965).
Sources: en.wikipedia.org
Rare polymorphisms related to this disease include (MTRR):c.1459G>A, (MTRR):c.1623-1624insTA and (MTRR):c.903+469T>C. These mutations, excluding (MTRR):c.1459G>A result in a frame shift, producing premature termination codons. As consequent products are distant from normal, mutant mRNA arises and nonsense mediated decay (FMN) is initiated. The large insertion of 903_904ins140 corresponding to 903+469T>C is most prevalent in CblE pathology. The activation of an enhanced splicer within intron 6 is incomplete, producing small quantities of normal spliced MTRR mRNA. Prenatal diagnosis of this condition is possible using [14C] methyltetrahydrofolate. Mutation analysis in native chorionic villi and [14C] formate in amino acids within these villi or cultured amniocytes is indicative of the CblE defect. Additionally, macrocytic anemia is a typical feature of the CblE defect and can be corrected though OH-Cobalamin administration or folate supplementation.
== Diver's harness == The diver's harness is an item of strong webbing, and sometimes cloth, which is fastened around a diver over the exposure suit, and allows the diver to be lifted without risk of falling out of the harness. Several types are in use.
==== Soil vacuum extraction ==== This form of remediation is possibly the most widely accepted in-situ technology for the removal of NAPLs in the unsaturated zone. Soil vacuum extraction (SVE) increases the volatility of NAPLs by using a vacuum that induces air flow. This process transforms NAPL into the gaseous phase and then strips those gaseous components from the subsurface, allowing them to be extracted and treated. Less volatile compounds can have their volatility increased using the application of heat, which is then followed with SVE. Multiphase extraction involves an 18–26 inch mercury vacuum that can simultaneously extract gaseous, aqueous, and immiscible phases of NAPL. Additionally, SVE is thought to enhance aerobic degradation of NAPLs, improving cost effectiveness by reducing the amount of required above-ground treatment.
SMRT sequencing is based on the sequencing by synthesis approach. The DNA is synthesized in zero-mode wave-guides (ZMWs) – small well-like containers with the capturing tools located at the bottom of the well. The sequencing is performed with use of unmodified polymerase (attached to the ZMW bottom) and fluorescently labelled nucleotides flowing freely in the solution. The wells are constructed in a way that only the fluorescence occurring by the bottom of the well is detected. The fluorescent label is detached from the nucleotide upon its incorporation into the DNA strand, leaving an unmodified DNA strand. According to Pacific Biosciences (PacBio), the SMRT technology developer, this methodology allows detection of nucleotide modifications (such as cytosine methylation). This happens through the observation of polymerase kinetics. This approach allows reads of 20,000 nucleotides or more, with average read lengths of 5 kilobases. In 2015, Pacific Biosciences announced the launch of a new sequencing instrument called the Sequel System, with 1 million ZMWs compared to 150,000 ZMWs in the PacBio RS II instrument. SMRT sequencing is referred to as "third-generation" or "long-read" sequencing.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.